Pentamidine Isethionate for Injection and Pentamidine Isethionate for Inhalation

XGen Pharmaceuticals DJB, Inc. is pleased to announce U.S. Food and Drug Administration (USFDA) approval for two new additions to their expanding product line.  Launching simultaneously in July 2023, XGen DJB will have availability of Pentamidine Isethionate for Inhalation and Pentamidine Isethionate for Injection.  This achievement marks two of six planned product launches over the next 12 months, giving credence to XGen DJB’s stated focus – developing and delivering specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices.

Pentamidine Isethionate for Inhalation, a generic therapeutic equivalent of Nebupent® (pentamidine isethionate), will be supplied in single-dose vials each containing 300 mg of powder, individually packaged as 1 vial per carton under NDC 39822-3030-2. 

Pentamidine Isethionate for Injection, a generic therapeutic equivalent of Pentam® 300 (pentamidine isethionate), will be supplied in single dose-vials each containing 300 mg of powder, packaged as 10 vials per carton under NDC 39822-3050-2. 

“Our investment into the development of new strategic generic injectable pharmaceutical products over the past three years is starting to produce results” commented Edmund Vanderbeck, President of XGen Pharmaceuticals, DJB.  “This is the start of our goal to launch 4 to 6 new products every year”

For additional information and full prescribing information for both products, visit

Pentam® 300 and Nebupent® are registered trademarks of Fresenius Kabi USA, LLC.